DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation

被引:31
作者
Chalkias, S. [1 ,2 ]
Mackenzie, M. R. [2 ]
Gay, C. [3 ]
Dooley, C. [4 ]
Marty, F. M. [3 ]
Moss, R. B. [5 ]
Li, T. [5 ]
Routh, R. L. [5 ]
Walsh, S. R. [2 ,3 ]
Tan, C. S. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Dept Med, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pharm, Boston, MA 02215 USA
[5] Ansun BioPharma, San Diego, CA USA
关键词
parainfluenza; DAS181; HSCT; mechanical ventilation; INFECTIONS; THERAPY; RISK;
D O I
10.1111/tid.12177
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) patients. DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease.
引用
收藏
页码:141 / 144
页数:4
相关论文
共 11 条
[1]   The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation [J].
Chemaly, Roy F. ;
Hanmod, Santosh S. ;
Rathod, Dhanesh B. ;
Ghantoji, Shashank S. ;
Jiang, Ying ;
Doshi, Arpan ;
Vigil, Karen ;
Adachi, Javier A. ;
Khoury, Andrew M. ;
Tarrand, Jeffery ;
Hosing, Chitra ;
Champlin, Richard .
BLOOD, 2012, 119 (12) :2738-2745
[2]   Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation [J].
Chen, Yi-Bin ;
Driscoll, Jessica P. ;
McAfee, Steven L. ;
Spitzer, Thomas R. ;
Rosenberg, Eric S. ;
Sanders, Rebecca ;
Moss, Ronald B. ;
Fang, Fang ;
Marty, Francisco M. .
CLINICAL INFECTIOUS DISEASES, 2011, 53 (07) :E77-E80
[3]   DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient [J].
Drozd, D. R. ;
Limaye, A. P. ;
Moss, R. B. ;
Sanders, R. L. ;
Hansen, C. ;
Edelman, J. D. ;
Raghu, G. ;
Boeckh, M. ;
Rakita, R. M. .
TRANSPLANT INFECTIOUS DISEASE, 2013, 15 (01) :E28-E32
[4]   Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients [J].
Guzman-Suarez, B. B. ;
Buckley, M. W. ;
Gilmore, E. T. ;
Vocca, E. ;
Moss, R. ;
Marty, F. M. ;
Sanders, R. ;
Baden, L. R. ;
Wurtman, D. ;
Issa, N. C. ;
Fang, F. ;
Koo, S. .
TRANSPLANT INFECTIOUS DISEASE, 2012, 14 (04) :427-433
[5]   End Points for Testing Influenza Antiviral Treatments for Patients at High Risk of Severe and Life-Threatening Disease [J].
Ison, Michael G. ;
de Jong, Menno D. ;
Gilligan, Kevin J. ;
Higgs, Elizabeth S. ;
Pavia, Andrew T. ;
Pierson, Jerome ;
Hayden, Frederick G. .
JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (11) :1654-1662
[6]   Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease [J].
Moscona, A .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (07) :1688-1698
[7]   A Recombinant Sialidase Fusion Protein Effectively Inhibits Human Parainfluenza Viral Infection In Vitro and In Vivo [J].
Moscona, Anne ;
Porotto, Matteo ;
Palmer, Samantha ;
Tai, Caroline ;
Aschenbrenner, Lori ;
Triana-Baltzer, Gallen ;
Li, Qi-Xiang ;
Wurtman, David ;
Niewiesk, Stefan ;
Fang, Fang .
JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (02) :234-241
[8]   A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection [J].
Moss, Ronald B. ;
Hansen, Carrie ;
Sanders, Rebecca L. ;
Hawley, Stephen ;
Li, Tiejun ;
Steigbigel, Roy T. .
JOURNAL OF INFECTIOUS DISEASES, 2012, 206 (12) :1844-1851
[9]  
National Institute of Allergy and Infectious Diseases, 2013, DAS181 PAT PAR
[10]   The use of sialidase therapy for respiratory viral infections [J].
Nicholls, John M. ;
Moss, Ronald B. ;
Haslam, Stuart M. .
ANTIVIRAL RESEARCH, 2013, 98 (03) :401-409